SA¹ú¼Ê´«Ã½

Friday 11 April 2025
Salisbury Foundation Trust

FOI_8380

Internal Reference Number: FOI_8380

Date Request Received: 15/01/2025 00:00:00

Date Request Replied To: 28/01/2025 00:00:00

This response was sent via: By Email

Request Summary: Spinal Muscular Atrophy

Request Category: Researcher

 
Question Number 1:
We have a freedom of information request related to the diagnosis and treatment of Spinal Muscular Atrophy. Your answers to the following questions would be greatly appreciated.

How many patients have a current diagnosis for Spinal Muscular Atrophy (ICD-10 Code G12.0, G12.1, G12.8 and G12.9) at your trust?
 
Answer To Question 1:
20 patients
 
Question Number 2:
How many patients have been treated in the last 4 months (September to December 2024) with the following products:

• Evrysdi (Risdiplam) - total patients

• Spinraza (Nusinersen) - total patients

• Zolgensma (Onasemnogene) - total patients

• Evrysdi (Risdiplam) – new* patients

• Spinraza (Nusinersen) – new* patients

• Zolgensma (Onasemnogene) – new* patients

*new patients are defined as patients who were not treated with any of Spinraza (Nusinersen), Evrysdi (Risdiplam) or Zolgensma (Onasemnogene) in the previous 4-month period (May to August 2024).

 
Answer To Question 2:
Response from Pharmacy: Pharmacy do not stock and  have not issued any of the 3 treatments listed in this FOI

Response from Spinal: We do not use any of these medications. It is prescribed by Neurologists.
 
Question Number 3:
Of the total patients treated in the last 4 months (September to December 2024) with Evrysdi (Risdiplam), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (May to August 2024).

 
Answer To Question 3:
Response from Pharmacy: Pharmacy do not stock and  have not issued any of the 3 treatments listed in this FOI
 
Question Number 4:
Of the total patients treated in the last 4 months (September to December 2024) with Zolgensma (Onasemnogene), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (May to August 2024).


 
Answer To Question 4:
Response from Pharmacy: Pharmacy do not stock and have not issued any of the 3 treatments listed in this FOI
 
Question Number 5:
How many patients have been treated with Zolgensma (Onasemnogene) in the last 12 months (January to December 2024)?
 
Answer To Question 5:
Response from Pharmacy: Pharmacy do not stock and  have not issued any of the 3 treatments listed in this FOI
 
To return to the list of all the FOI requests please click here

Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Person Centred & Safe

Professional

Responsive

Friendly

Progressive

SA¹ú¼Ê´«Ã½, SA¹ú¼Ê´«Ã½ Hospital, Odstock Road, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2025 SA¹ú¼Ê´«Ã½
Trust Values